Personalised human albumin in patients with cirrhosis and ascites: design and rationale for the ALB-TRIAL - a randomised clinical biomarker validation trial

Autor: Torben Hansen, Pere Ginès, Wim Laleman, Peer Bork, Vishal C Patel, Debbie Shawcross, Robert Schierwagen, Camila Alvarez-Silva, Florence Servant, Jonel Trebicka, Benjamin Lelouvier, Manimozhiyan Arumugam, Ed J Kuijper, Frank Erhard Uschner, Michael Praktiknjo, Mária Papp, Saeed Shoaie, Michael Kühn, Maja Thiele, Paolo Angeli, Joan Claria, Vicente Arroyo, Manolo Laiola, Benoit Quinquis, Sabine Klein, Minneke J Coenraad, François Fenaille, Debbie Lindsay Shawcross, Wenyi Gu, Adria Juanola, Elisa Pose, Aleksander Krag, Ivica Letunic, Alain Pruvost, Hervé M Blottière, Nathalie Galleron, Cristina López-Vicario, Peter V Treit, Matthias Mann, Jelle Matthijnssens, Mark J W Mcphail, Philipp E Geyer, Hans Olav Melberg, Stefanie Kandels, Cristina Sánchez-Garrido, Florence A Castelli, Christophe Junot, Lars Asphaug, Mads Israelsen, Helene Bæk Juel, Nikolaj Torp, Minneke Coenraad, Marko Korenjak, Ferran Aguilar-Parera, Patricia Sierra-Casas, Anna Bosch-Comas, David Tornai, Boglarka Balogh, Katrine Holtz Thorhauge, Casper Sahl Poulsen, Thea Van Rossum, Suguru Nishijima, Marisa I Keller, Diënty H M Hazenbrink, Sylvain Dechaumet, Sebastian D Burz, Emeline Chu-Van, Etienne Thévenot, Florian A Rosenberger, Sebastian Van Blerk, Amirouche Ouzerdine, Alain Roulet, Jean-Louis-Marie Insonere, Céline Serres, Mathieu Almeida, Florence Thirion, Camille Champion, Chaima Ezzine, Célia Chamignon, Nicolas Lapaque, Mamadou Gabou Thiam, Lore Van Espen, Quinten R Ducarmon, Annelotte GC Broekhoven, Susan Fischer, Romy Zwittink, Itziar De Lecuona, Giulio Rosati, Celia Fuentes-Chust, Arben Merkoçi, Massimo Urban, José Alfonso Marrugo-Ramirez, Ameli Schwalber, Lindsey Ann Edwards, Victoria Tatiana Kronsten, David Moyes, Azadeh Harzandi, Jordi Gratacós-Ginès, Martina Pérez-Guasch, Miriam Pellón, Bryan Contreras, Max Brol, Manfred Fobker, Renata Antonina Feuerborn

Publikováno v: BMJ Open, Vol 14, Iss 2 (2024)

Introduction Human albumin is used in the treatment of complications of cirrhosis. However, the use of long-term human albumin administration is costly and resource demanding for both patients and healthcare systems. A precision medicine approach wit

Externí odkaz: https://doaj.org/article/289f12a27d2047adb5cb758cb2809703

Emerging medical therapies for severe alcoholic hepatitis

Autor: David Tornai, Gyongyi Szabo

Publikováno v: Clinical and Molecular Hepatology, Vol 26, Iss 4, Pp 686-696 (2020)

Severe alcoholic hepatitis (AH) is an acute and often devastating form of alcohol-associated liver disease. Clinically, AH is characterized by elevated bilirubin, model for end stage liver disease scores >20, and nonspecific symptoms that are caused

Externí odkaz: https://doaj.org/article/91fe922c68be4724bf5c22c3d6e4613d

Inhibition of the Inflammasome Signaling Cascade Reduces Alcohol Consumption in Female But Not Male Mice

Autor: Patrick Lowe, Sahin Coban, David Tornai, Donna Catalano, Yeonhee Cho, Gyongyi Szabo

Publikováno v: Alcohol Clin Exp Res

BACKGROUND Alcohol use disorder is a significant societal and medical burden that is associated with both organ pathology and addiction. Excessive alcohol use results in neuroinflammation characterized by activation of the inflammasome, a multiprotei

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d96a045a266165b701a1ee1167a98521
https://doi.org/10.1111/acer.14272

Neutrophil extracellular traps contribute to liver damage and increase defective low-density neutrophils in alcohol-associated hepatitis

Autor: Yeonhee Cho, Terence Ndonyi Bukong, David Tornai, Mrigya Babuta, Ioannis S. Vlachos, Eleni Kanata, Donna Catalano, Gyongyi Szabo

Publikováno v: Journal of hepatology. 78(1)

In alcohol-associated hepatitis (AH), inflammation and neutrophil counts correlate with poor clinical outcomes. Here, we investigated how neutrophils contribute to liver damage in AH.We isolated blood neutrophils from individuals with AH to examine n

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03fcc6a5f214519e865e19cc92fa58d7
https://pubmed.ncbi.nlm.nih.gov/36063965

Emerging medical therapies for severe alcoholic hepatitis

Autor: Gyongyi Szabo, David Tornai

Publikováno v: Clinical and Molecular Hepatology
Clinical and Molecular Hepatology, Vol 26, Iss 4, Pp 686-696 (2020)

Severe alcoholic hepatitis (AH) is an acute and often devastating form of alcohol-associated liver disease. Clinically, AH is characterized by elevated bilirubin, model for end stage liver disease scores >20, and nonspecific symptoms that are caused

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36318905c05c59f9257116cb0df67ef6
https://pubmed.ncbi.nlm.nih.gov/32981291